KCM
PCRX icon

Kingdon Capital Management’s Pacira BioSciences PCRX Stock Holding History

Kingdon Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-195,700
Closed -$6.27M – 123
2018
Q2 		$6.27M Buy
+195,700
New +$6.76M 0.44% 77

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Kingdon Capital Management's PCRX Position: Q3 2016 in Review

Kingdon Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2016, closing a stake of 211,500 shares — an estimated $7.13M sold.

Kingdon Capital Management first reported a position in PCRX in Q2 2013 and held it in 3 quarters. The position peaked at $7.13M in Q2 2016. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

  • Kingdon Capital Management reported no remaining Pacira BioSciences position as of Q3 2016 after selling out during the quarter.
  • Kingdon Capital Management sold 211,500 Pacira BioSciences shares in Q3 2016, an estimated $7.13M.
  • Kingdon Capital Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 3 quarters.
  • Kingdon Capital Management's Pacira BioSciences position peaked at $7.13M in Q2 2016.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on Kingdon Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.